Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Withdrawal From Diabetes Drugs Research May Help Glenmark (India) "

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals is expected to benefit from a recent announcement by Merck KGaA that the international drug-maker is stopping all research and development for diabetes drugs. Currently, Merck and the India-based Glenmark have a E190 million licensing deal for Glenmark's experimental diabetes treatment, GRC 8200. The deal would have given Merck the right to market the drug in Japan, Europe, and the United States while Glenmark retained the Indian rights. Merck already paid Glenmark E25 million for the drug when it was in initial clinical trials, last year. Since that time, GRC 8200 has progressed into later-stage human testing, making it much more attractive to investors. Now, with the return of the licensing rights, Glenmark may be able to sell the molecule for a higher price to a third-party. Despite Merck's withdrawal, development of the drug is expected to continue on schedule. (Click here for more

You may also be interested in...



China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel